Skip to main content

Table 2 Motor nerve conduction tests in patients with HD, ALS or CSA

From: Electrophysiological differences between Hirayama disease, amyotrophic lateral sclerosis and cervical spondylotic amyotrophy

  Median nerve Ulnar nerve U/M ratio
  Amplitude (mV) CV (m/s) Amplitude (mV) CV (m/s) Amplitude CV
HD Affected limb 8.2 ± 3.9& 59.3 ± 4.3 3.2 ± 2.6& 60.3 ± 5.5 0.55 ± 0.41& 1.02 ± 0.11
  Healthy limb 10.3 ± 2.4 60.2 ± 3.5 9.0 ± 1.9 59.3 ± 4.2 0.98 ± 0.22 1.03 ± 0.11
ALS Affected limb 2.3 ± 2.2*& 55.5 ± 4.5*& 4.8 ± 3.5*& 56.6 ± 6.0*& 2.28 ± 1.25*& 1.10 ± 0.18
  Healthy limb 7.9 ± 2.4# 54.8 ± 3.9* 8.4 ± 2.4 55.2 ± 4.2# 1.12 ± 0.32 1.04 ± 0.14
CSA Affected limb 4.5 ± 3.1*& 57.4 ± 5.2 4.9 ± 3.1*& 55.1 ± 4.1*& 1.21 ± 0.53* 0.95 ± 0.13
  Healthy limb 8.2 ± 2.0# 57.2 ± 3.2* 7.8 ± 1.8# 55.2 ± 4.3* 0.97 ± 0.34 0.93 ± 0.17
Normal controls   9.0 ± 1.5 59.8 ± 3.1 9.5 ± 1.8 60.2 ± 3.2 1.15 ± 0.23 1.01 ± 0.12
  1. *P < 0.0001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected (healthy) limbs of patients with HD.
  2. #P < 0.001, the affected (healthy) limbs of patients with ALS or CSA vs. the affected (healthy) limbs of patients with HD.
  3. &P < 0.0001, the affected limbs of patients with HD, ALS or CSA patients vs. the limbs of normal controls.
  4. HD, Hirayama disease; ALS, amyotrophic lateral sclerosis; CSA, cervical spondylotic amyotrophy; CV, conduction velocities; U/M, ulnar/median.